ClinicalTrials.gg

Program

SPY002

A development code. Also written as “SPY002-091”.

Its studies are mostly in Colitis, Ulcerative, led by Spyre Therapeutics.

Furthest: phase 2, since May 27, 20253 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Spyre Therapeutics32 open or runningphase 2since May 27, 2025Nov 1, 2024Jun 2027phase 2 · NCT07012395

Also a collaborator on its studies: altasciences-company-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2024First study: phase 1 study in HealthyFirst studyNCT06672718 · 50 enrolled · United States
  2. May 27, 2025Phase 2 study in Colitis, UlcerativeNCT07012395 · 645 planned · United States, Argentina, Australia and more
  3. Jun 11, 2026Phase 2 study in Colitis, UlcerativeNCT07652294 · 645 planned · United States, Argentina, Australia and more

Ahead

  1. Jun 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07012395
  2. Mar 2, 2029Primary completion: phase 2 study in Colitis, UlcerativeNCT07652294

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07652294Colitis, Ulcerative · United States, Argentina, Australia and more2By invitationMar 2, 2029645
NCT07012395Colitis, Ulcerative · United States, Argentina, Australia and more2RecruitingJun 2027645
NCT06672718Healthy · United States1CompletedAug 19, 202650

How it is read

Names in the registry

  • “SPY002”, 2 entries
  • “SPY002-091”, 1 entry

Codes read as this program: SPY002, SPY002091.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
SPY002 (Spyre Therapeutics): development program | ClinicalTrials.gg